Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Gynecol Obstet Hum Reprod ; 50(7): 101994, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33217600

ABSTRACT

OBJECTIVE: To evaluate a thrombin gel matrix (TGM), Floseal, for the prevention of lymphocele in patients with endometrial cancer who underwent pelvic lymphadenectomy. METHODS: A total of 79 consecutive patients with endometrial cancer were randomly allocated to one of two groups: the TGM group and control group. After completion of the lymphadenectomy, 5 mL of Floseal was applied to the bilateral pelvic sidewalls, especially the femoral canal, obturator, and common iliac vessels areas. Computed tomography scans were obtained for lymphocele evaluation 2 months after the surgery. RESULTS: Three patients from the TGM group, and four patients from the control group were lost during follow-up, and data from 36 participants from each group were analyzed. As the primary outcome, lymphocele developed in 12 patients in both groups (33 %). There was no significant difference between the groups in terms of lymphocele and symptomatic lymphocele development. Lymphocele localization was also not different between the two groups, but the diameter of the lymphoceles detected in the TGM group was significantly greater (p = 0.021). The mean drainage days was significantly shorter in the TGM group (p = 0.015). The amount of drainage was also less in the TGM group, but the difference was not statistically significant. CONCLUSION: Thrombin gel matrix applied to the pelvic sidewalls does not reduce the incidence of symptomatic or asymptomatic lymphoceles after pelvic lymphadenectomy in endometrial cancer. However, it can reduce the amount of drainage and the number of drainage days so it can help to shorten hospitalization.


Subject(s)
Endometrial Neoplasms/drug therapy , Gelatin Sponge, Absorbable/therapeutic use , Lymphocele/prevention & control , Aged , Endometrial Neoplasms/complications , Female , Gelatin Sponge, Absorbable/administration & dosage , Humans , Incidence , Lymph Node Excision/methods , Lymphocele/drug therapy , Middle Aged , Prospective Studies , Thrombin/administration & dosage , Thrombin/therapeutic use
2.
Eur J Med Res ; 18: 18, 2013 Jun 24.
Article in English | MEDLINE | ID: mdl-23800048

ABSTRACT

BACKGROUND: Human HIV-1 TAT interactive protein 2 (HTATIP2/TIP30) is an evolutionarily conserved gene that is expressed ubiquitously in human tissues and some tumor tissues. This protein has been found to be associated with some gynecological cancers; as such, this study aimed to investigate blood HTATIP2/TIP30 levels in patients with ovarian cancer. METHODS: Twenty-three women with ovarian cancer and 18 patients with various non-cancerous gynecological complaints (for example, dysfunctional uterine bleeding, fibroids, and urinary incontinence) were included in the study. The pathological diagnosis of ovarian cancer was adenocarcinoma. HTATIP2/TIP30 concentration in the patients' blood samples was determined using ELISA kits. RESULTS: The HTATIP2/TIP30 level was significantly higher in the cancer group than in the control group (1.84 ± 0.82 versus 0.57 ± 0.13 ng/ml, mean ± SD). CONCLUSIONS: We demonstrated the potential role of HTATIP2/TIP30 in ovarian cancer for the first time, thereby enlightening future studies targeting HTATIP2/TIP30 in ovarian cancer treatment, diagnosis, and prevention.


Subject(s)
Acetyltransferases/blood , Adenocarcinoma/blood , Genital Diseases, Female/blood , Ovarian Neoplasms/blood , Transcription Factors/blood , Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Diagnosis, Differential , Female , Genital Diseases, Female/diagnosis , Genital Diseases, Female/pathology , HIV Infections/metabolism , HIV Infections/pathology , HIV Infections/virology , HIV-1/metabolism , HIV-1/pathogenicity , Humans , Middle Aged , Molecular Targeted Therapy , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/pathology , Prognosis
3.
Eurasian J Med ; 43(1): 57-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-25610162

ABSTRACT

Postpartum hemorrhage is one of the major causes of maternal mortality. There are medical and surgical options to control the bleeding, some of which can impair future fertility. Transcatheter arterial embolization might be a useful option in the management of intractable postpartum bleeding before the consideration of more invasive and radical methods. In this report, we report a 33-year-old patient who presented with primary postpartum hemorrhage due to vaginal laceration and was eventually treated with transcatheter arterial embolization.

SELECTION OF CITATIONS
SEARCH DETAIL
...